PD-1/PD-L1 and CTLA-4 inhibitors enhance antitumor immunity across gynecological cancers, with high ORRs in PD-L1-positive cervical tumors, microenvironment modulation in ovarian cancer, and novel combinations overcoming resistance in endometrial cancer. Here, CTLA4 is linked to ovarian carcinoma.